Neuropsychological functions and metabolic aspects in subclinical hypothyroidism: The effects of l-thyroxine

Marina Baldini, Alessandro Colasanti, Alessandra Orsatti, Lorena Airaghi, Massimo C. Mauri, Maria Domenica Cappellini

Research output: Contribution to journalArticle

Abstract

Thyroid hypofunction is a slowly progressing graded phenomenon [Vanderpump MP, Tunbridge WM, French JM, Appleton D, Bates D, Clark F, et al. The incidence of thyroid disorders in the community: a twenty-year follow-up of the Whickham Survey. Clin Endocrinol (Oxf) 1995;43(1):55-68]; subclinical forms (SCH) often represent a laboratory diagnosis in apparently asymptomatic patients. In the absence of adequate parameters for thyroid hormone action in tissues, the level of TSH increase corresponding to negative effects remains unsettled. We studied a wide range of physiological processes in a strictly selected population of 38 female patients (56.4 ± 12.6 years) with minor forms of SCH (TSH 6.6 ± 1.8 mIU/L), after exclusion of neurological, psychiatric and somatic disorders or confounding conditions. The investigations, performed at admission and after 6 months of l-thyroxine (LT4) treatment, included metabolic evaluation, health status perception and an extensive battery of neuropsychological tests and psychological rating scales. Lipid metabolism improved after LT4 (total cholesterol: 231.9 ± 49.6 mg/dl pre- vs 221.0 ± 40.0 mg/dl post-treatment; LDL cholesterol: 183.1 ± 62.9 vs 162.7 ± 53.7 mg/dl; apolipoprotein A1: 183.5 ± 64.5 vs 160.9 ± 50.3 mg/dl; p <0.05 for all comparisons), while glucose metabolism was unchanged. Health status perception was favourably influenced by the treatment (total SF-36 score 97.8 ± 18.4 pre- vs 108.5 ± 14.8 post-, p <0.0001); in a matched control group with euthyroid goiter, tested to examine the effects of medical care in the absence of treatment, no significant differences were found in the SF-36 scores at admission and after 6 months (109.3 ± 15.1 vs 109 ± 14.2, p = 0.9). Attention performance improved after LT4; HRSD and HRSA scores did not significantly change, but negative correlations were found between FT3 levels and affective scores at admission, and between the post-treatment changes of affective scores and of FT3. In our study subtle disturbances of health status perception, attention and lipid metabolism associated to SCH of mildest degrees were reverted by LT4 replacement, reinforcing reports of unfavourable consequences of marginal thyroid disease.

Original languageEnglish
Pages (from-to)854-859
Number of pages6
JournalProgress in Neuro-Psychopharmacology and Biological Psychiatry
Volume33
Issue number5
DOIs
Publication statusPublished - Aug 1 2009

Fingerprint

Hypothyroidism
Thyroxine
Health Status
Lipid Metabolism
Thyroid Gland
Physiological Phenomena
Therapeutics
Clinical Laboratory Techniques
Neuropsychological Tests
Apolipoprotein A-I
Thyroid Diseases
Thyroid Hormones
LDL Cholesterol
Psychiatry
Research Design
Cholesterol
Psychology
Glucose
Control Groups
Incidence

Keywords

  • Health status
  • Neuropsychological functions
  • Subclinical hypothyroidism

ASJC Scopus subject areas

  • Biological Psychiatry
  • Pharmacology

Cite this

@article{1dfe3610cb164ddb959298ba597819af,
title = "Neuropsychological functions and metabolic aspects in subclinical hypothyroidism: The effects of l-thyroxine",
abstract = "Thyroid hypofunction is a slowly progressing graded phenomenon [Vanderpump MP, Tunbridge WM, French JM, Appleton D, Bates D, Clark F, et al. The incidence of thyroid disorders in the community: a twenty-year follow-up of the Whickham Survey. Clin Endocrinol (Oxf) 1995;43(1):55-68]; subclinical forms (SCH) often represent a laboratory diagnosis in apparently asymptomatic patients. In the absence of adequate parameters for thyroid hormone action in tissues, the level of TSH increase corresponding to negative effects remains unsettled. We studied a wide range of physiological processes in a strictly selected population of 38 female patients (56.4 ± 12.6 years) with minor forms of SCH (TSH 6.6 ± 1.8 mIU/L), after exclusion of neurological, psychiatric and somatic disorders or confounding conditions. The investigations, performed at admission and after 6 months of l-thyroxine (LT4) treatment, included metabolic evaluation, health status perception and an extensive battery of neuropsychological tests and psychological rating scales. Lipid metabolism improved after LT4 (total cholesterol: 231.9 ± 49.6 mg/dl pre- vs 221.0 ± 40.0 mg/dl post-treatment; LDL cholesterol: 183.1 ± 62.9 vs 162.7 ± 53.7 mg/dl; apolipoprotein A1: 183.5 ± 64.5 vs 160.9 ± 50.3 mg/dl; p <0.05 for all comparisons), while glucose metabolism was unchanged. Health status perception was favourably influenced by the treatment (total SF-36 score 97.8 ± 18.4 pre- vs 108.5 ± 14.8 post-, p <0.0001); in a matched control group with euthyroid goiter, tested to examine the effects of medical care in the absence of treatment, no significant differences were found in the SF-36 scores at admission and after 6 months (109.3 ± 15.1 vs 109 ± 14.2, p = 0.9). Attention performance improved after LT4; HRSD and HRSA scores did not significantly change, but negative correlations were found between FT3 levels and affective scores at admission, and between the post-treatment changes of affective scores and of FT3. In our study subtle disturbances of health status perception, attention and lipid metabolism associated to SCH of mildest degrees were reverted by LT4 replacement, reinforcing reports of unfavourable consequences of marginal thyroid disease.",
keywords = "Health status, Neuropsychological functions, Subclinical hypothyroidism",
author = "Marina Baldini and Alessandro Colasanti and Alessandra Orsatti and Lorena Airaghi and Mauri, {Massimo C.} and Cappellini, {Maria Domenica}",
year = "2009",
month = "8",
day = "1",
doi = "10.1016/j.pnpbp.2009.04.009",
language = "English",
volume = "33",
pages = "854--859",
journal = "Progress in Neuro-Psychopharmacology and Biological Psychiatry",
issn = "0278-5846",
publisher = "Elsevier Inc.",
number = "5",

}

TY - JOUR

T1 - Neuropsychological functions and metabolic aspects in subclinical hypothyroidism

T2 - The effects of l-thyroxine

AU - Baldini, Marina

AU - Colasanti, Alessandro

AU - Orsatti, Alessandra

AU - Airaghi, Lorena

AU - Mauri, Massimo C.

AU - Cappellini, Maria Domenica

PY - 2009/8/1

Y1 - 2009/8/1

N2 - Thyroid hypofunction is a slowly progressing graded phenomenon [Vanderpump MP, Tunbridge WM, French JM, Appleton D, Bates D, Clark F, et al. The incidence of thyroid disorders in the community: a twenty-year follow-up of the Whickham Survey. Clin Endocrinol (Oxf) 1995;43(1):55-68]; subclinical forms (SCH) often represent a laboratory diagnosis in apparently asymptomatic patients. In the absence of adequate parameters for thyroid hormone action in tissues, the level of TSH increase corresponding to negative effects remains unsettled. We studied a wide range of physiological processes in a strictly selected population of 38 female patients (56.4 ± 12.6 years) with minor forms of SCH (TSH 6.6 ± 1.8 mIU/L), after exclusion of neurological, psychiatric and somatic disorders or confounding conditions. The investigations, performed at admission and after 6 months of l-thyroxine (LT4) treatment, included metabolic evaluation, health status perception and an extensive battery of neuropsychological tests and psychological rating scales. Lipid metabolism improved after LT4 (total cholesterol: 231.9 ± 49.6 mg/dl pre- vs 221.0 ± 40.0 mg/dl post-treatment; LDL cholesterol: 183.1 ± 62.9 vs 162.7 ± 53.7 mg/dl; apolipoprotein A1: 183.5 ± 64.5 vs 160.9 ± 50.3 mg/dl; p <0.05 for all comparisons), while glucose metabolism was unchanged. Health status perception was favourably influenced by the treatment (total SF-36 score 97.8 ± 18.4 pre- vs 108.5 ± 14.8 post-, p <0.0001); in a matched control group with euthyroid goiter, tested to examine the effects of medical care in the absence of treatment, no significant differences were found in the SF-36 scores at admission and after 6 months (109.3 ± 15.1 vs 109 ± 14.2, p = 0.9). Attention performance improved after LT4; HRSD and HRSA scores did not significantly change, but negative correlations were found between FT3 levels and affective scores at admission, and between the post-treatment changes of affective scores and of FT3. In our study subtle disturbances of health status perception, attention and lipid metabolism associated to SCH of mildest degrees were reverted by LT4 replacement, reinforcing reports of unfavourable consequences of marginal thyroid disease.

AB - Thyroid hypofunction is a slowly progressing graded phenomenon [Vanderpump MP, Tunbridge WM, French JM, Appleton D, Bates D, Clark F, et al. The incidence of thyroid disorders in the community: a twenty-year follow-up of the Whickham Survey. Clin Endocrinol (Oxf) 1995;43(1):55-68]; subclinical forms (SCH) often represent a laboratory diagnosis in apparently asymptomatic patients. In the absence of adequate parameters for thyroid hormone action in tissues, the level of TSH increase corresponding to negative effects remains unsettled. We studied a wide range of physiological processes in a strictly selected population of 38 female patients (56.4 ± 12.6 years) with minor forms of SCH (TSH 6.6 ± 1.8 mIU/L), after exclusion of neurological, psychiatric and somatic disorders or confounding conditions. The investigations, performed at admission and after 6 months of l-thyroxine (LT4) treatment, included metabolic evaluation, health status perception and an extensive battery of neuropsychological tests and psychological rating scales. Lipid metabolism improved after LT4 (total cholesterol: 231.9 ± 49.6 mg/dl pre- vs 221.0 ± 40.0 mg/dl post-treatment; LDL cholesterol: 183.1 ± 62.9 vs 162.7 ± 53.7 mg/dl; apolipoprotein A1: 183.5 ± 64.5 vs 160.9 ± 50.3 mg/dl; p <0.05 for all comparisons), while glucose metabolism was unchanged. Health status perception was favourably influenced by the treatment (total SF-36 score 97.8 ± 18.4 pre- vs 108.5 ± 14.8 post-, p <0.0001); in a matched control group with euthyroid goiter, tested to examine the effects of medical care in the absence of treatment, no significant differences were found in the SF-36 scores at admission and after 6 months (109.3 ± 15.1 vs 109 ± 14.2, p = 0.9). Attention performance improved after LT4; HRSD and HRSA scores did not significantly change, but negative correlations were found between FT3 levels and affective scores at admission, and between the post-treatment changes of affective scores and of FT3. In our study subtle disturbances of health status perception, attention and lipid metabolism associated to SCH of mildest degrees were reverted by LT4 replacement, reinforcing reports of unfavourable consequences of marginal thyroid disease.

KW - Health status

KW - Neuropsychological functions

KW - Subclinical hypothyroidism

UR - http://www.scopus.com/inward/record.url?scp=67649354044&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67649354044&partnerID=8YFLogxK

U2 - 10.1016/j.pnpbp.2009.04.009

DO - 10.1016/j.pnpbp.2009.04.009

M3 - Article

C2 - 19389454

AN - SCOPUS:67649354044

VL - 33

SP - 854

EP - 859

JO - Progress in Neuro-Psychopharmacology and Biological Psychiatry

JF - Progress in Neuro-Psychopharmacology and Biological Psychiatry

SN - 0278-5846

IS - 5

ER -